Ionis, Biogen Down on Ending Development of ALS Drug
Posted
Zacks (via Benzinga)
Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced their decision to terminate the development of their investigational amyo
read more
